Clinical trials: Rejection
Cytomegalovirus Infection, Renal Transplant Failure
Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate
Despite the improvement of efficacy results with current immunosuppressive regimens (about 15% of incidence of acute rejection), the security schemes used do not show the same results.The most worldwide used regime is tacrolimus…
- Conditions
- Cytomegalovirus Infection, Renal Transplant Failure, Transplant; Complication, Rejection
- Trial name
- NCT01354301
- Testing
- Thymoglobulin, Everolimus, Basiliximabe
- Where
- Brazil
- Volunteers
- 300 people
- Sponsor
- Hospital do Rim e Hipertensão
Kidney Transplant Rejection, Kidney Transplant; Complications
Australian Genomics Of Chronic Allograft Dysfunction Study
The goal of the Australian Genomics of Chronic Allograft Dysfunction (AUSCAD) study is a single centre (Westmead Hospital), prospective, observational study, which enrols patients at time of kidney (or kidney-transplant)…
- Trial name
- AUSCAD (NCT06314230)
- Where
- 2 sites in Australia
- Volunteers
- 500 people
- Sponsor
- Western Sydney Local Health District
Bronchiolitis Obliterans, Lung Transplantation
Montelukast in Bronchiolitis Obliterans Syndrome
Chronic rejection (or Bronchiolitis Obliterans syndrome-BOS) is a major cause of mortality and morbidity after lung transplantation.
- Conditions
- Bronchiolitis Obliterans, Lung Transplantation, Graft Rejection
- Trial name
- MLK002 (NCT01211509)
- Testing
- Montelukast
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
HIV Infections, Renal Transplant Rejection
Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant
This is an open-label study, where participants will be switched from their current HIV medication to the study drug, BIC/F/TAF. Open-label means both the investigator and the participant will know what drug will be given.
- Trial name
- NCT04530630
- Testing
- BIC/F/TAF 50Mg-200Mg-25Mg Tablet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
Chronic Rejection, Kidney Insufficiency
Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients
The purpose of this study is to determine if administration of rituximab blocks the development of donor specific antibodies (DSA) in transplant recipients who have developed renal dysfunction and DSA after renal transplant.
- Trial name
- NCT00261547
- Testing
- Rituximab
- Sponsor
- Massachusetts General Hospital
Graft Vs Host Disease
Evaluation of the Impact of Reduced Immunosuppression
Graft-versus-host disease (GVHD) is a life-threatening complication of transplantation. It occurs when the donor graft contains immunologically competent T-cells that recognize the recipient as foreign.
- Trial name
- NCT05238155
- Testing
- antimetabolite
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Methodist Health System
Kidney Transplantation
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
The purpose of the study in de novo renal transplant patients is to evaluate the effect on renal function of an optimized new regimen in comparison with the standard everolimus exposure plus a low-dose cyclosporine microemulsion…
- Trial name
- NCT00170885
- Testing
- Everolimus
- Where
- Switzerland
- Sponsor
- Novartis
Kidney Failure
Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
This study will test the safety and effectiveness of two drugs, Sirolimus and Thymoglobulin, for preventing rejection of transplanted kidneys.
- Trial name
- NCT00006178
- Testing
- Sirolimus, Thymoglobulin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney Transplant Failure and Rejection, Immunosuppression-related Infectious Disease
Tacrolimus Pharmacokinetic Subpopulations
This prospective study will investigate the concentrations of tacrolimus metabolites (M-I and M-III) over the four first years post-transplantation.
- Trial name
- TIPS (NCT04526431)
- Testing
- Dosage Forms Oral
- Where
- 2 sites in France
- Volunteers
- 180 people
- Sponsor
- University Hospital, Grenoble
Renal Transplant Rejection, Fibrosis
Mesenchymal Stromal Cell Therapy in Renal Recipients
This study will test the hypothesis that MSCs in combination with Everolimus facilitate Tacrolimus withdrawal, reduce fibrosis and decrease the incidence of opportunistic infections compared to standard tacrolimus dose.
- Trial name
- MSCs (NCT02057965)
- Testing
- Mesenchymal Stromal Cells
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- Leiden University Medical Center
Kidney Rejection Transplant
Molecular Landscape of Microvascular Inflammation in Kidney Allografts
Microvascular inflammation in kidney allografts has been widely reappraised in the recent update of Banff classification. There is a critical need to better understand the pathophysiological mechanisms associated with the various…
- Trial name
- NCT06342128
- Testing
- No intervention
- Where
- 3 sites in France
- Volunteers
- 600 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Kidney Transplant Rejection
TruGraf and TRAC In Pediatrics Study
This is a pilot 3 center prospective study of pediatric renal kidney recipients undergoing protocol biopsies examining the performance of the TruGraf gene expression test in children and adolescents.
- Trial name
- TTIPS (NCT05335538)
- Testing
- Patients monitored with TruGraf and TRAC testing
- Where
- 3 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- Transplant Genomics, Inc.
Kidney Transplant Rejection
Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance
Prospective Observational Multicenter Cohort. External validation of donor derived cell free DNA in Renal Transplantation. Assessing performance of dd-cfDNA as a surveillance tool and its association with clinical outcomes.
- Trial name
- ADMIRAL (NCT04566055)
- Testing
- AlloSure
- Where
- 8 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- CareDx
Kidney Transplantation, Acute Graft Rejection
Pre-formed Alloreactivity in Renal Transplant Recipients
This investigator-initiated study will analyse the role of pre-formed alloreactive T cells on acute rejection episodes and graft outcome in kidney transplant recipients after living donation.
- Trial name
- NCT02633826
- Where
- 13 sites in Germany
- Volunteers
- 190 people
- Sponsor
- Martina Sester
Transplant
Immune Function as Predictor of Infectious Complications and Clinical Outcome in Patients Undergoing Solid Organ Transplantation
At Rigshospitalet, Denmark, we will examine the immune function of solid organ transplant recipients before and at several timepoints after transplantation as well as the clinical outcome, especially the risk of infections…
- Trial name
- Immune-Mo (NCT03847285)
- Testing
- solid organ transplantation
- Where
- Denmark
- Volunteers
- 188 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Heart Transplant Failure
Tacrolimus and Personalized Therapy to Prevent Acute Rejection Episodes
Heart transplant is the only effective treatment for people with advanced heart failure. Post-transplant pharmacological therapies are of fundamental importance for the survival of individuals after surgery: although considerable…
- Trial name
- NCT06338306
- Testing
- Tacrolimus（FK506）
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Renal Transplant Rejection
Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection
The purpose of this study is to determine the feasibility and efficacy of detecting kidney transplant rejection using contrast enhance ultrasonography with the contrast agent Sonazoid.
- Trial name
- NCT02733029
- Testing
- Sonazoid, contrast enhanced ultrasonography
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Brigham and Women's Hospital
Kidney Transplantation
Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant
The safety and efficacy of FTY720 is being evaluated in patients who receive a kidney transplant.
- Trial name
- NCT00099801
- Testing
- FTY720
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant Failure and Rejection
Assessment of QSant™ for Underlying Allograft Rejection
The AQUA registry is a multi-center observational study to assess the clinical management of kidney transplant recipients (KTRs) with use of the QSant test.
- Trial name
- AQUA (NCT05282966)
- Testing
- QSant-TM Urine Test
- Volunteers
- 4,000 people
- Sponsor
- NephroSant
Heart Transplant Failure and Rejection
Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation
The study objective is to demonstrate that rejection surveillance of heart transplant recipients with Prospera dd-cfDNA is non-inferior to rejection surveillance with endomyocardial biopsy and histology in the first…
- Trial name
- DETECT (NCT05081739)
- Testing
- Prospera Transplant Assessment, Endomyocardial biopsy
- Sponsor
- Natera, Inc.